Causal AI to learn “Gemini Digital Twins” for Drug Discovery and Clinical Development: Join our CMO, Bruce Church at AIRIS 2024
We are excited to announce that Aitia will be participating at the AI Regulatory & International Symposium 2024 conference in Seoul, Korea. Our Chief Mathematics Officer, Bruce Church, will be taking the stage in the New Medical Products and Treatment Opportunities Using AI session to talk about Aitia’s commitment in accelerating AI-driven discoveries and share […]
Meet us at WSJ Health Forum
Join our CEO, Colin Hill with an influential community of scientists, business leaders, investors, policymakers and experts from across the sector to explore the trends, technologies, ideas and opportunities reshaping the business and science of health on Feb 21, 2024 in Boston at WSJ Forum. Find more details here.
Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease
Aitia‘s Gemini Digital Twins will help identify subpopulations of patients who could respond favorably to Servier’s LRRK2 in development treatment Suresnes (France), 08 January 2024 – Servier, an independent international pharmaceutical group, and Aitia, the leader in the application of causal AI and Digital Twins, have strengthened today their partnership by signing a new contract […]
Meet us at J.P.Morgan Healthcare Conference
As we prepare to wrap up another exciting year for Aitia, we’re eagerly looking forward to a bustling 2024. For now, we’re gearing up for the J.P. Morgan conference, where our CEO, Colin Hill and President, COO, Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the […]
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement WILMINGTON, Mass. & Somerville, Mass. – November 13, 2023: Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia, a leader in the application of Causal AI and […]
Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia’s Digital Twins to be Presented at SfN 2023
Somerville, MA, November 8, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer’s Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from […]
Driving the Discovery and Clinical Development of the Next Generation of Alzheimer’s Disease Drugs: Join us at the CNS Summit 2023
We are thrilled to announce that Aitia will be participating in the CNS Summit 2023 conference. Colin Hill, will be joined by Rudolph Tanzi, Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, and Ole Isacson, Professor & Chair […]
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
Somerville, MA, October 19, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer’s Disease Digital Twins will be presented at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD), being held from October 24-27, 2023 in Boston. Aitia’s Digital […]
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]
Leveraging AI in Healthcare and Life Sciences Discussion: Join our CEO, Colin Hill at the Sixth Annual International IP Summit
We are delighted to announce that Aitia will be participating in the Sixth Annual International IP Summit. Our CEO, Colin Hill, will be a featured speaker at an engaging discussion titled: Leveraging AI in Healthcare and Life Sciences: Key Legal Considerations. Colin will be joined by industry experts Dr. Bernardo Bizzo, the Senior Director of […]